AVM Biotechnology

AVM is developing AVM0703, a therapeutic that induces highly active endogenous γδ TCR+ Invariant TCR+ NKT cells with indications in cancer & T1D.

[AVM Biotechnology @avmbiotech]

If you missed us, please reach out to [email protected] to learn about the excitement surrounding AVM0703.

[AVM Biotechnology @avmbiotech]

That's a wrap for #ASH23! Thanks to all who stopped by our booth and learned more about AVM Biotechnology's clinical program. It was a pleasure to see the fascinating new hematologic research and be surrounded by dedicated colleagues. Wishing all attendees safe travels home!

[AVM Biotechnology @avmbiotech]

#ASH23 is here! We are excited to be attending ASH 2023 in San Diego this weekend. If you'll be attending this year, we would love to meet with you at the AVM Biotechnology Booth #112. Wishing everyone an informative and productive meeting!

[ASH @ASH_hematology]

Don't miss the premier event in #hematology 🩸 Come network with the top minds in the field at #ASH23 and get access to the latest science with hundreds of abstract presentations. Register now: https://t.co/p4ZKfHWyxF

[AVM Biotechnology @avmbiotech]

@ASH_hematology Looking forward to a great conference! #ASH23

[AVM Biotechnology @avmbiotech]

AVM Biotechnology would like to give special thanks to @NCIsbir for our selection as a 2023 Showcase Company and sponsoring our presence at the @BIOConvention Investor Forum. We greatly value your partnership and guidance to make this presentation great!

[AVM Biotechnology @avmbiotech]

At the Bio Investor Forum in October, our CSO Dr. Theresa Deisher gave a company presentation highlighting AVM0703 and the important work happening at AVM Biotechnology. Watch a recording of the exciting presentation here: https://t.co/LtSXlvpWFb

[AVM Biotechnology @avmbiotech]

This collaboration is evaluating how AVM0703 can help reverse T1D in an early clinical setting. We strive to have a positive impact on treating this debilitating disease and are honored to raise awareness alongside the NIDDK!

[AVM Biotechnology @avmbiotech]

November is National #DiabetesMonth! Take steps to manage diabetes and prevent diabetes health problems with tips from @NIDDKgov: https://t.co/AQ2WsrA5nT

#Diabetes #DiabetesAwareness

[AVM Biotechnology @avmbiotech]

AVM Biotechnology is a proud recipient of multiple
@NIDDKgov grants to explore how AVM0703 might contribute to the delay or prevention of Type 1 Diabetes. As part of our most recent grant award, we are collaborating with the @UF.

[AVM Biotechnology @avmbiotech]

AVM Biotechnology is giving a company presentation tomorrow, 10/18, at 10:15 AM at the BIO Investor Forum in San Francisco. We are honored to be sponsored at the forum by the NCI as one of their showcase portfolio companies. Come and learn about the unique cancer drug from AVM!

[AVM Biotechnology @avmbiotech]

We are excited to be presenting at the BIO Investor Forum in San Francisco October 17-18th.
Attending? For potential partners and investors, please email [email protected] to schedule a meeting.
#BIOSanFrancisco #AVMBiotechnology #Investors

https://t.co/4ATVfUAWJK

[AVM Biotechnology @avmbiotech]

We are excited to be an SBIR showcase company for 2023-2024 and look forward to our innovation and mission being presented to investors and potential partners!
If you're interested in learning more about partnership opportunities, please reach out to [email protected]

[AVM Biotechnology @avmbiotech]

AVM Biotechnology Announces that the National Cancer Institute has selected AVM Biotechnology as a Showcase Company for their 2023-2024 Small Business Innovation Research (SBIR) Investor Initiatives
https://t.co/kt2Ba3yPeY

[AVM Biotechnology @avmbiotech]

AVM Biotechnology Announces that the National Cancer Institute has selected AVM Biotechnology as a Showcase Company for their 2023-2024 Small Business Innovation Research (SBIR) Investor Initiatives
https://t.co/kt2Ba3yPeY

[AVM Biotechnology @avmbiotech]

@MedTechNow_ @medigus3 @MontefioreNYC Thanks for the feature!

[BiotechTechNow @MedTechNow_]

#InTheClinic

@medigus3's to install wireless EV charging system with leading automatic carpark provider

#HeliusMedicalTechnologies announces participation of @MontefioreNYC in therapeutic experience program

@avmbiotech announces 28 #solidtumor, #BloodCancer patient milestone

[AVM Biotechnology @avmbiotech]

Today is #WorldLungCancerDay and we at AVM Biotechnology join the @LungAssociation in the mission to bring awareness to one of the most common types of cancer worldwide.

[AVM Biotechnology @avmbiotech]

AVM Biotechnology Announces Twenty-Eight (28) Solid Tumor and Blood Cancer Patients have been Treated with Immunomodulatory AVM0703
https://t.co/8LYp5zQVbC
#immunesystem #hope #cancertreatment #fightcancer #treatcancer #immunotherapy #cancersucks #StrongerThanCancer #beatcancer

[AVM Biotechnology @avmbiotech]

AVM Biotechnology has been chosen as a 2023/2024 winner/recognised enterprise in the NIH Small Business Innovation Research Grant program. #cancer #lymphoma #cure #clintonglobalinitiative #ElonMusk

[AVM Biotechnology @avmbiotech]

Providing compassionate use of AVM0703 to all types of no-option cancers with a 60% disease control/response rate compels us to let everyone know about this program. No hair loss, nausea, diarrhea or vomiting. Just some hope...#CancerDoesntWait #Cancer #lymphoma #elon_musk #hope

[AVM Biotechnology @avmbiotech]

AVM Awarded SBIR grant to study AVM0703 with R-CHOP in Non-Hodgkin's Lymphoma. https://t.co/iJ6WWWHdxR
#oncology #CancerResearch #cancertreatment